Want to see CPMD full AI Analyst Report?
Cannapharmarx (CPMD) Ratios
Cannapharmarx Ratios
CPMD's free cash flow for Q2 2026 was $243.66K. For the 2026 fiscal year, CPMD's free cash flow was increased by $4.00 and operating cash flow was $-127.37K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.04 | 0.04 | 0.07 | 0.01 | 0.00 |
| Quick Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Solvency Ratio | -0.30 | -0.32 | 0.16 | -0.36 | -0.68 |
| Operating Cash Flow Ratio | -0.02 | -0.07 | -0.13 | -0.08 | -0.19 |
| Short-Term Operating Cash Flow Coverage | -0.06 | -0.20 | -0.32 | -0.16 | -0.27 |
| Net Current Asset Value | $ -35.86M | $ -29.63M | $ -22.70M | $ -22.66M | $ -13.01M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 2.94 | 1.30 | 1.10 | 2.68 | 78.89 |
| Debt-to-Equity Ratio | -0.68 | -0.71 | -1.06 | -0.84 | -0.70 |
| Debt-to-Capital Ratio | -2.17 | -2.45 | 16.54 | -5.15 | -2.31 |
| Long-Term Debt-to-Capital Ratio | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -0.23 | -0.55 | -0.97 | -0.31 | -0.01 |
| Debt Service Coverage Ratio | -0.20 | -0.71 | -0.17 | -0.44 | -0.25 |
| Interest Coverage Ratio | -1.37 | -1.59 | -0.93 | -2.28 | -1.99 |
| Debt to Market Cap | 4.24 | 1.67 | 13.35 | 4.23 | 9.32 |
| Interest Debt Per Share | 0.03 | 0.03 | 0.05 | 0.08 | 0.14 |
| Net Debt to EBITDA | -6.35 | -1.84 | -8.94 | -2.96 | -3.44 |
| Profitability Margins | |||||
| Gross Profit Margin | -153.06% | -357.87% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -637.37% | -931.80% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -238.73% | -931.67% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -245.77% | -439.68% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -817.19% | -1207.85% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -817.19% | -1207.85% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -817.19% | -1207.85% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 332.50% | 274.71% | -233.27% | 163.68% | 295.09% |
| Return on Assets (ROA) | -158.60% | -91.42% | 31.40% | -157.57% | -7725.01% |
| Return on Equity (ROE) | 36.92% | 50.01% | -30.35% | 49.19% | 68.33% |
| Return on Capital Employed (ROCE) | 13.62% | 24.17% | 24.63% | 44.35% | 23.16% |
| Return on Invested Capital (ROIC) | 35.23% | 62.72% | -202.12% | 203.66% | 76.61% |
| Return on Tangible Assets | -158.60% | -91.42% | 31.40% | -157.57% | -7725.01% |
| Earnings Yield | -323.12% | -195.59% | 702.22% | -404.23% | -913.15% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.01 | 40.10 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.63 | 0.78 | 0.01 | 0.04 | 0.00 |
| Inventory Turnover | 3.09 | 3.77 | 0.06 | 4.30 | -8.11 |
| Fixed Asset Turnover | 0.24 | 0.15 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.19 | 0.08 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | -0.05 | -0.04 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -409.07 | -359.05 | -24835.84 | -8482.83 | -79561.77 |
| Days of Sales Outstanding | 52.05 | 9.10 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 118.10 | 96.84 | 6311.51 | 84.82 | -45.00 |
| Days of Payables Outstanding | 579.22 | 464.99 | 31147.35 | 8567.65 | 79516.76 |
| Operating Cycle | 170.15 | 105.94 | 6311.51 | 84.82 | -45.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.03 |
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.01 | -0.03 |
| Dividend Paid and CapEx Coverage Ratio | -142.98 | -848616.00 | -28.21 | -12.49 | -385.54 |
| Capital Expenditure Coverage Ratio | -142.98 | -848616.00 | -28.21 | -12.49 | -385.54 |
| Operating Cash Flow Coverage Ratio | -0.04 | -0.12 | -0.18 | -0.10 | -0.27 |
| Operating Cash Flow to Sales Ratio | -0.58 | -2.07 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -23.07% | -33.51% | -448.42% | -74.12% | -250.30% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.31 | -0.51 | 0.14 | -0.25 | -0.11 |
| Price-to-Sales (P/S) Ratio | 2.53 | 6.18 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -0.11 | -0.26 | -0.04 | -0.12 | -0.07 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -4.34 | -2.98 | -0.22 | -1.35 | -0.40 |
| Price-to-Operating Cash Flow Ratio | -4.37 | -2.98 | -0.23 | -1.46 | -0.40 |
| Price-to-Earnings Growth (PEG) Ratio | -0.05 | 0.00 | -0.00 | 0.00 | 0.00 |
| Enterprise Value Multiple | -7.41 | -2.50 | -9.30 | -3.38 | -3.81 |
| Enterprise Value | 24.09M | 19.12M | 13.46M | 16.63M | 9.96M |
| EV to EBITDA | -7.41 | -2.50 | -9.30 | -3.38 | -3.81 |
| EV to Sales | 17.69 | 23.32 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -30.32 | -11.27 | -5.72 | -10.63 | -4.11 |
| EV to Operating Cash Flow | -30.53 | -11.27 | -5.92 | -11.48 | -4.12 |
| Tangible Book Value Per Share | -0.05 | -0.03 | -0.04 | -0.08 | -0.17 |
| Shareholders’ Equity Per Share | -0.05 | -0.03 | -0.04 | -0.08 | -0.17 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.02 | -0.02 | 0.01 | -0.04 | -0.12 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.28 | 1.30 | -2.34 | 1.64 | 3.38 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.70 | 0.73 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.07 | 0.17 | -0.62 | 0.17 | 0.27 |
Currency in USD
